B3GALNT2 and neoplasm: Alterations in the expression of the B3GALNT2 gene, encoding β-1,3-N-acetylgalactosaminyltransferase 2, have been reported in cancer, being upregulated both its mRNA and protein product (the latter by 1.31-fold) in samples of hepatocellular carcinoma, and its levels directly correlating with tumor size and with a lower survival of patients with this tumor type [117].